Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Rhythm Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Update to September Conference Participation
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals to Present at Investor Conferences in September
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.